Profile data is unavailable for this security.
About the company
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.
- Revenue in USD (TTM)404.72k
- Net income in USD-5.44m
- Incorporated2004
- Employees5.00
- LocationLexaria Bioscience Corp100 - 740 MCCURDY ROADKELOWNA V1X 2P7CanadaCAN
- Phone+1 (250) 765-6424
- Fax+1 (604) 685-7602
- Websitehttps://www.lexariabioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hcw Biologics Inc | 2.84m | -24.99m | 42.74m | 45.00 | -- | 3.02 | -- | 15.04 | -0.6953 | -0.6953 | 0.0791 | 0.3737 | 0.0755 | -- | 2.91 | 63,150.89 | -66.37 | -- | -78.58 | -- | 19.72 | -- | -879.53 | -- | -- | -90.86 | 0.319 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Movano Inc | 0.00 | -29.28m | 42.75m | 30.00 | -- | 7.04 | -- | -- | -0.6463 | -0.6463 | 0.00 | 0.0618 | 0.00 | -- | -- | 0.00 | -258.41 | -151.50 | -496.87 | -188.58 | -- | -- | -- | -- | 1.26 | -- | 0.014 | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| Immuneering Corp | 0.00 | -54.18m | 43.00m | 65.00 | -- | 0.5462 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Xilio Therapeutics Inc | 0.00 | -76.40m | 43.56m | 73.00 | -- | 0.8846 | -- | -- | -2.78 | -2.78 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -76.37 | -- | -93.74 | -- | -- | -- | -- | -- | -- | -131.89 | 0.0826 | -- | -- | -- | 13.40 | -- | -- | -- |
| Aadi Bioscience Inc | 23.84m | -68.83m | 43.71m | 75.00 | -- | 0.4832 | -- | 1.83 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Matinas BioPharma Holdings Inc | 1.10m | -22.94m | 44.04m | 32.00 | -- | 1.98 | -- | 40.19 | -0.1056 | -0.1056 | 0.005 | 0.0886 | 0.0314 | -- | -- | 34,250.00 | -65.62 | -44.62 | -72.81 | -48.25 | -- | -- | -2,093.25 | -2,344.60 | -- | -- | 0.0012 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| Ocuphire Pharma Inc | 19.05m | -9.99m | 44.05m | 14.00 | -- | 0.8264 | -- | 2.31 | -0.4735 | -0.4735 | 0.8727 | 2.08 | 0.3701 | -- | 5.30 | 1,360,643.00 | -19.40 | -58.31 | -20.77 | -65.94 | -- | -- | -52.42 | -137.92 | -- | -8.46 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| IN8BIO, Inc. | 0.00 | -30.01m | 44.46m | 31.00 | -- | 1.75 | -- | -- | -1.02 | -1.02 | 0.00 | 0.5761 | 0.00 | -- | -- | 0.00 | -89.91 | -74.18 | -108.07 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Gain Therapeutics Inc | 55.18k | -22.27m | 45.31m | 29.00 | -- | 3.23 | -- | 821.14 | -1.74 | -1.74 | 0.0042 | 0.7761 | 0.0026 | -- | 0.2544 | 1,902.76 | -104.28 | -- | -132.41 | -- | -- | -- | -40,354.33 | -13,827.07 | -- | -- | 0.0432 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Lexaria Bioscience Corp | 404.72k | -5.44m | 45.74m | 5.00 | -- | 6.74 | -- | 113.03 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| NextCure Inc | 0.00 | -63.73m | 46.16m | 82.00 | -- | 0.4648 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Earth Science Tech Inc | 5.98m | 330.94k | 47.23m | 8.00 | 156.25 | 21.88 | 89.23 | 7.89 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 7.88m | -69.20m | 48.04m | 100.00 | -- | 0.426 | -- | 6.10 | -1.83 | -1.83 | 0.2083 | 2.96 | 0.0406 | -- | -- | 78,760.00 | -35.71 | -48.32 | -40.23 | -54.03 | -- | -- | -878.58 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Rockwell Medical Inc | 83.61m | -8.44m | 48.16m | 237.00 | -- | 2.24 | -- | 0.576 | -0.3947 | -0.3947 | 3.59 | 0.7309 | 1.69 | 12.82 | 9.74 | 352,793.30 | -17.08 | -46.29 | -26.18 | -65.38 | 10.41 | 4.66 | -10.09 | -36.51 | 1.38 | -3.77 | 0.3329 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
| Medicine Man Technologies Inc | 172.45m | -42.70m | 48.68m | 729.00 | -- | 0.3857 | -- | 0.2823 | -1.60 | -1.60 | 3.01 | 1.61 | 0.5064 | 3.99 | 39.49 | 236,553.90 | -10.15 | -8.33 | -11.95 | -9.85 | 44.08 | 45.57 | -20.03 | -15.71 | 0.5027 | 0.3143 | 0.5679 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
Data as of May 10 2024. Currency figures normalised to Lexaria Bioscience Corp's reporting currency: US Dollar USD
8.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invenomic Capital Management LPas of 31 Dec 2023 | 731.98k | 5.78% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 85.16k | 0.67% |
| Waystone Fund Management (IE) Ltd.as of 31 Dec 2022 | 64.09k | 0.51% |
| Geode Capital Management LLCas of 31 Dec 2023 | 53.59k | 0.42% |
| Raymond James Financial Services Advisors, Inc.as of 31 Mar 2024 | 39.55k | 0.31% |
| Citadel Securities LLCas of 31 Dec 2023 | 29.56k | 0.23% |
| The Welch Group LLCas of 31 Mar 2024 | 24.00k | 0.19% |
| Wealth Enhancement Advisory Services LLCas of 31 Mar 2024 | 10.32k | 0.08% |
| Tower Research Capital LLCas of 31 Dec 2023 | 5.81k | 0.05% |
| Oakworth Capital, Inc. (Investment Management)as of 31 Mar 2024 | 5.00k | 0.04% |
More ▼
Data from 31 Dec 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
